This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AGLE Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aeglea BioTherapeutics Stock (NASDAQ:AGLE) Get Aeglea BioTherapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$9.47▼$13.7652-Week Range N/AVolume43,300 shsAverage Volume95,409 shsMarket Capitalization$48.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Read More Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGLE Stock News HeadlinesSpyre Therapeutics Advances IBD Treatment PipelineNovember 9, 2024 | markets.businessinsider.comNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, PredictionsFebruary 21, 2024 | benzinga.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 17 at 2:00 AM | Banyan Hill Publishing (Ad)Bridge Biotherapeutics Inc.January 30, 2024 | wsj.comSpyre Therapeutics Announces $180 Million Private PlacementDecember 7, 2023 | finance.yahoo.comAeglea Biotherapeutics announces name change to Spyre TherapeuticsNovember 27, 2023 | msn.comAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRENovember 27, 2023 | markets.businessinsider.comAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNovember 27, 2023 | finance.yahoo.comSee More Headlines AGLE Stock Analysis - Frequently Asked Questions How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its earnings results on Thursday, November, 4th. The biotechnology company reported ($7.75) earnings per share for the quarter, missing analysts' consensus estimates of ($7.00) by $0.75. The biotechnology company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%. When did Aeglea BioTherapeutics' stock split? Aeglea BioTherapeutics's stock reverse split before market open on Friday, September 8th 2023.The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aeglea BioTherapeutics IPO? Aeglea BioTherapeutics (AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeglea BioTherapeutics investors own include Bristol Myers Squibb (BMY), Athenex (ATNX), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD), Amarin (AMRN), Axsome Therapeutics (AXSM) and AbbVie (ABBV). Company Calendar Last Earnings11/04/2021Today9/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGLE CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees69Year Founded2013Profitability EPS (Trailing Twelve Months)($75.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.82 million Net Margins-22,195.36% Pretax Margin-27,931.12% Return on Equity-132.05% Return on Assets-146.87% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.59 Sales & Book Value Annual Sales$2.33 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($60.61) per share Price / BookN/AMiscellaneous Outstanding Shares4,050,000Free Float3,782,000Market Cap$48.64 million OptionableOptionable Beta2.57 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AGLE) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeglea BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.